SHS Capital and LPs Invest ~€10M in Develco Pharma

October 7, 2024

SHS Capital, together with its limited partners and other existing shareholders, is investing approximately €10 million in Develco Pharma to expand manufacturing capacity and accelerate product development in response to exceptionally strong demand. Develco, a specialty pharma developer and manufacturer of modified-release formulations headquartered in Pratteln (DACH region), has been backed by SHS since 2020 and reports an order book exceeding 12 months of revenue.

Buyers
SHS Capital, SHS Capital limited partners, Other shareholders
Targets
Develco Pharma
Industry
Pharmaceuticals
Location
Basel-Landschaft, Switzerland
Transaction Type
Growth capital

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.